GGGerardo Guinto

Gerardo Guinto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gerardo Guinto has a total of 130 co-authors. Here are the top co-authors by number of shared publications:

  • Norma Aréchiga

    Centro Médico ABC, Mexico City, Mexico

    12 shared publications
  • Miguel Abdo

    Department of Neurosurgery, Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Mexico City, Mexico

    8 shared publications
  • Moisés Mercado

    Instituto Mexicano del Seguro Social

    8 shared publications
  • Erick Zepeda

    Dr. Guinto is Professor and Chairman, Department of Neurosurgery, Dr. Abdo is Associate Professor, Department of Neurosurgery, Dr. Aréchiga is Associate Professor, Department of Neurology, and Dr. Zepeda is Associate Professor, Department of Neurosurgery, Hospital de Especialidades del Centro Médico Nacional Siglo XXI; mail to: Hospital Angeles del Pedregal, Periferico Sur 3697-1025, Colonia Héroes de Padierna, CP 10700, México City, México;

    6 shared publications
  • Yoshiaki Guinto-Nishimura

    Universidad Panamericana School of Medicine, Mexico City, Mexico

    6 shared publications
  • David Gallardo

    Hospital Angeles Del Pedregal, Mexico City, Mexico

    5 shared publications

Latest Publications

  • Open Access

    Association between Intracellular Calcium Signaling and Tumor Recurrence in Human Non-Functioning Pituitary Adenomas

    by Yorgui Santiago-Andres, Ana Aquiles, Keiko Taniguchi-Ponciano, Latife Salame, Gerardo Guinto, Moises Mercado, Tatiana Fiordelisio

    Clinically non-functioning pituitary adenomas (CNFPAs) are the second most frequent sellar tumor among studies on community-dwelling adults. They are characterized by the absence of hormonal hypersecretion syndrome, and patients present with compressive symptoms, such as a headache and visual field defects. Immunohistochemically, most CNFPAs are of gonadotrope differentiation, with only a few of them being truly null cell adenomas. Although these tumors express receptors for one or more hypothalamic releasing hormones, to what extent this has an impact on the biological and clinical behavior of these neoplasms remains to be defined. In this research, we evaluated the basal and hypothalamic secretagogue-stimulated intracellular calcium mobilization in 13 CNFPAs, trying to correlate this response to the phenotypic features of the patients. Our results indicate that the recurrence of a CNFPA correlates positively with cellular responsiveness, as measured by spontaneous intracellular calcium activity and the ability to respond to multiple hypothalamic secretagogues. We conclude that this finding may be a useful tool for predicting the clinicopathologic behavior of CNFPAs, by testing the variation of cellular responsiveness to hypothalamic secretagogues.


  • Open Access

    Current and Future Perspectives of Microscopic and Endoscopic Transsphenoidal Surgery for Pituitary Adenomas: A Narrative Review

    by Gerardo Guinto, Gerardo Y. Guinto-Nishimura, Marcos V. Sangrador-Deitos, Rodrigo Uribe-Pacheco, Rene Soto-Martinez, David Gallardo, Patricia Guinto, Alejandro Vargas, Norma Aréchiga


  • Open Access

    The Genomic Landscape of Corticotroph Tumors: From Silent Adenomas to ACTH-Secreting Carcinomas

    by Sergio Andonegui-Elguera, Gloria Silva-Román, Eduardo Peña-Martínez, Keiko Taniguchi-Ponciano, Sandra Vela-Patiño, Ilan Remba-Shapiro, Erick Gómez-Apo, Ana-Laura Espinosa-De-Los-Monteros, Lesly A. Portocarrero-Ortiz, Gerardo Guinto, et al.

    Corticotroph cells give rise to aggressive and rare pituitary neoplasms comprising ACTH-producing adenomas resulting in Cushing disease (CD), clinically silent ACTH adenomas (SCA), Crooke cell adenomas (CCA) and ACTH-producing carcinomas (CA). The molecular pathogenesis of these tumors is still poorly understood. To better understand the genomic landscape of all the lesions of the corticotroph lineage, we sequenced the whole exome of three SCA, one CCA, four ACTH-secreting PA causing CD, one corticotrophinoma occurring in a CD patient who developed Nelson syndrome after adrenalectomy and one patient with an ACTH-producing CA. The ACTH-producing CA was the lesion with the highest number of single nucleotide variants (SNV) in genes such as USP8, TP53, AURKA, EGFR, HSD3B1 and CDKN1A. The USP8 variant was found only in the ACTH-CA and in the corticotrophinoma occurring in a patient with Nelson syndrome. In CCA, SNV in TP53, EGFR, HSD3B1 and CDKN1A SNV were present. HSD3B1 and CDKN1A SNVs were present in all three SCA, whereas in two of these tumors SNV in TP53, AURKA and EGFR were found. None of the analyzed tumors showed SNV in USP48, BRAF, BRG1 or CABLES1. The amplification of 17q12 was found in all tumors, except for the ACTH-producing carcinoma. The four clinically functioning ACTH adenomas and the ACTH-CA shared the amplification of 10q11.22 and showed more copy-number variation (CNV) gains and single-nucleotide variations than the nonfunctioning tumors.


  • Open Access

    Petroclival Meningiomas: A Simple System That Could Help in Selecting the Approach

    by Gerardo Guinto, Eli Hernández, Eric Estrada, David Gallardo, Miguel Kageyama, Norma Aréchiga, Gerardo Y Guinto-Nishimura

    BACKGROUND: Petroclival meningiomas (PCM) represent a neurosurgical challenge due to their strategic location close to the brainstem. OBJECTIVE: To assess the applicability of a retrosigmoid approach (RSA) by analyzing the degree of displacement of the middle cerebellar peduncle (MCP) elicited by PCM. METHODS: Patients with PCM were prospectively included and divided into those whose imaging studies showed that the posterior end of the MCP was displaced by the tumor and were eligible for and underwent RSA (group A) and those who were not eligible for RSA and who underwent surgery via a posterior transpetrosal approach (group B). We compared tumor behavior, clinical characteristic of patients and surgical results. RESULTS: Twenty patients with PCM were enrolled and allocated to group A (n = 15) or group B (n = 5). The clinical manifestations were more severe in group B; tumors in this group were larger and gross total removal was achieved in only 1 patient (20%). In comparison, in 12 cases on group A, tumors could be totally removed (80%) and all of these patients could recover their quality of life after surgery. CONCLUSION: To our knowledge, this study is the first to consider displacement of the MCP when establishing a suitable surgical approach for PCM. Our results suggest that the RSA becomes increasingly suitable when peduncle displacement is greater. By using this method, it was also possible to identify two types of tumors: petroclivals (group A) and clivopetrosals (group B), that show some specific clinical and surgical differences.


  • Open Access

    Anatomical Basis of the Zygomatic-Transmandibular Approach: Operative Video

    by Gerardo Guinto, Eli Hernandez, David Gallardo-Ceja, Francisco Gallegos-Hernandez, Norma Arechiga, Gerardo Guinto-Nishimura

    Tumor growth in infratemporal fossa (ITF) and parapharyngeal space (PPS) is generally slow and generates very few clinical manifestations, so it is not uncommon for tumors to reach large dimensions at the time of diagnosis, making necessary to perform ample approaches. In zygomatic-transmandibular approach (ZTMA), the access of the ITF and PPS is obtained by a combination of a pterional craniotomy plus a zygomatic-mandibular osteotomy. Tumor excision is achieved by its initial dissection from all of the neurovascular structures of the middle fossa by the neurosurgical team and the final resection by the head and neck team from below. In the first part of this video, we present a brief anatomical–surgical description of the ITF and PPS and in the second part, we show case of a trigeminal schwannoma that could be successfully removed through a ZTMA. Using this approach, an ample and safe exposure of the ITF and PPS is achieved, without affecting the chewing or facial nerve function and with excellent cosmetic results, so it can be considered as a reliable surgical option, particularly in cases of giant tumors that affect these regions ([Figs. 1] and [2]). The link to the video can be found at: https://youtu.be/oxVFhzT8HsQ. Received: 11 September 2020 Accepted: 09 January 2021 Publication Date: 03 May 2021 (online) © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Open Access

    Proteomic and Transcriptomic Analysis Identify Spliceosome as a Significant Component of the Molecular Machinery in the Pituitary Tumors Derived from POU1F1- and NR5A1-Cell Lineages

    by Keiko Taniguchi-Ponciano, Eduardo Peña-Martínez, Gloria Silva-Román, Sandra Vela-Patiño, Ana Laura Guzman-Ortiz, Hector Quezada, Erick Gomez-Apo, Laura Chavez-Macias, Sophia Mercado-Medrez, Guadalupe Vargas-Ortega, et al.

    Background: Pituitary adenomas (PA) are the second most common tumor in the central nervous system and have low counts of mutated genes. Splicing occurs in 95% of the coding RNA. There is scarce information about the spliceosome and mRNA-isoforms in PA, and therefore we carried out proteomic and transcriptomic analysis to identify spliceosome components and mRNA isoforms in PA. Methods: Proteomic profile analysis was carried out by nano-HPLC and mass spectrometry with a quadrupole time-of-flight mass spectrometer. The mRNA isoforms and transcriptomic profiles were carried out by microarray technology. With proteins and mRNA information we carried out Gene Ontology and exon level analysis to identify splicing-related events. Results: Approximately 2000 proteins were identified in pituitary tumors. Spliceosome proteins such as SRSF1, U2AF1 and RBM42 among others were found in PA. These results were validated at mRNA level, which showed up-regulation of spliceosome genes in PA. Spliceosome-related genes segregate and categorize PA tumor subtypes. The PA showed alterations in CDK18 and THY1 mRNA isoforms which could be tumor specific. Conclusions: Spliceosome components are significant constituents of the PA molecular machinery and could be used as molecular markers and therapeutic targets. Splicing-related genes and mRNA-isoforms profiles characterize tumor subtypes.


  • Open Access

    Utility of gene tumor expression of VEGF, FOXM1*3 and CD-133 on diagnosis and prognosis of brain gliomas

    by Iris Angélica Feria-Romero, Bárbara Nettel-Rueda, Marco Antonio Rodríguez-Florido, Ignacio Félix-Espinoza, Luis Castellanos-Pallares, Jesús Cienfuegos-Meza, Sandra Orozco-Suárez, Jesús A. Chavez, Consuelo Escamilla-Nuñez, Gerardo Guinto, et al.

    Objective: This paper seeks to quantify the normalized expression of transcripts FOXM1*3, VEGF, CD133 , and MGMT and their relation with the histopathological and molecular diagnosis and with the probability of estimating tumor progression-free survival of gliomas. Methods: A cohort of patients was made up of patients aged over 18 years with a histological and molecular diagnosis of gliomas from the year 2011 to 2018. The patients had a complete tumor resection. Patients with high-grade glioma received adjuvant management (temozolamide and radiotherapy). Clinical and imaging follow-up was carried out periodically to identify the time of progression free survival (PFS). Results: Ninety-one patients (age range, 18–85 years) comprised the study cohort with a predominance of males. The expression of FOXM1*3, VEGF , and CD133 allowed the differentiation of astrocytomas grade II from GBM. ROC curves proved statistically significant in the GBM model ( p < 0.05), demonstrating greatest sensitivity with FOXM1*3 (91%), and greatest specificity with VEGF (93%). The age-adjusted Cox multivariate model established that a PFS 50% of 25 months corresponds to a median value of 5.3 for VEGF and 0.42 for CD133. Conclusions: The normalized expression of transcripts FOXM1 *3, VEGF , and CD133 allow us to estimate the probability of PFS, especially in gliomas grades II and IV; likewise, their overexpression defines the diagnosis of GBM. Authorship: Substantial contributions to conception and design (IAFR, BNR, MARF, GG, IG), acquisition of data (IAFR, BNR, MARF, IFE, LCP, JCM, SOS, JAC, CRA), analysis and interpretation of data (IAFR, BNR, MARF, JCM, SOS, CEN, HMG, IG). Drafting the article (IAFR, BNR, MARF, IFE, LCP, SOS, JAC, IG), revising it critically for important intellectual content (IAFR, JCM, CEN, GG, HMG, CRA, IG) Final approval of the version to be published (IAFR, BNR, MARF, IFE, LCP, JCM, SOS, JAC, CEN, GG, HMG, CRA, IG).


  • Osseous Remodeling Technique of the Sella Turcica: A New Surgical Option for Primary Empty Sella Syndrome

    by Gerardo Guinto, Barbara Nettel, Eli Hernández, David Gallardo, Norma Aréchiga, Moisés Mercado


  • Neurosurgical Residency Training in Latin America: Current Status, Challenges, and Future Opportunities

    by Ricardo Murguia-Fuentes, Nuruddin Husein, Alfonso Vega, Leonardo Rangel-Castilla, J. Marcus Rotta, Alfredo Quinones-Hinojosa, Gerardo Guinto, Yoshua Esquenazi


  • Neurenteric Cyst: Is It Really a Benign Lesion?

    by Victor Correa-Correa, Gerardo Guinto, Guillermo Castellanos, Erick Zepeda, Bayron A. Sandoval-Bonilla, Juan Carlos Gonzalez-Rodriguez, Cesar Alejandro Zecchini-Heredia, Samuel Romero-Vargas